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program expansion. The health insurance exchanges will
act as marketplaces for people to shop for and compare
health insurance plans in their state. There are three models
of health insurance exchanges: federally facilitated, state
run and partnership exchanges that have input from both
the state and federal governments. Each state chose to
create their own exchange or to have the federal govern-
ment create and operate their state exchange. The ex-
changes present an opportunity for people to access
affordable health insurance through federal tax credits that
will subsidize premiums for individuals and families up to
400 percent of the federal poverty level (FPL). The ex-
changes are expected to enroll 7 million people in the ﬁrst
year of the ACA. Each exchange will offer a variety of qual-
iﬁed health plans (QHP) that are approved by the state and/
or the US Department of Health and Human Services (HHS).
Every QHP and non-grandfathered commercial health in-
surance plan is mandated to include a minimum level of
coverage known as an essential health beneﬁt (EHB) pack-
age selected by each state. Information was collected on
each state’s EHB plan to determine coverage of hemato-
poietic cell transplantation (HCT), and was analyzed for the
level of HCT beneﬁts with consideration of the Recom-
mended Beneﬁt Design For HCT developed by the National
Marrow Donor Program (NMDP) (www.payor.bethematch-
clinical.org). States were then divided into three categories:
poor coverage, fair coverage and excellent coverage. Eleven
states had poor coverage, 12 states had fair coverage and 28
states had excellent coverage included in their EHBs. While
access to health insurance is expanding, it is important that
coverage of HCT meets levels prescribed in the Recom-
mended Beneﬁt Design For HCT. Additionally, states were
able to expand their state Medicaid programs to include
adults up to 138 percent of the FPL. To date, twenty-ﬁve
states are expanding their Medicaid programs, resulting in
increased access for low-income adults in their states. In
states that expanded their Medicaid programs, 31,587,000
adults are now eligible to access to health insurance
coverage through Medicaid (Kaiser Family Foundation). A
study done by the NMDP provides HCT incidence rates that
translates to a possible 2,148 Medicaid patients needing an
allogeneic HCT following Medicaid expansion by states that
have already voted to expand in the ﬁrst year of ACA
implementation. Transplant centers will need to under-
stand how their state operates in each of these three aspects
in order to provide patients with access to HCT in 2014 and
beyond.161
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Background:Match related donors (MRDs) have long been a
critical source of stem cells for patients needing an allogeneic
transplant. In both our center and across the country,
approximately 30% of patients needing an allogeneic trans-
plant will have a matched sibling who can serve as their
donor. While the National Marrow Donor Program (NMDP)
and other donor registries have done extensive research in to
the donor experience for unrelated donors, much less is
known about the experience of donors who are related to thepatient. As part of an effort to improve our services to these
patients, we implemented a donor satisfaction survey spe-
ciﬁcally targeting these donors.
Methods: We assessed both the current hospital patient
survey and the current NMDP donor survey and designed a
survey that would be delivered to adult peripheral blood and
marrow MRDs on the ﬁrst day of collection. We assessed
satisfaction with medical care, effectiveness of administra-
tive coordination efforts, and barriers to donation. We then
reviewed individual surveys and compiled the feedback to
assess needed changes.
Results: In the ﬁrst 6 months, we distributed the survey to
44 patients and received a 50% response rate. Our overall
satisfaction rating was quite high (4.9 out of 5), with
approximately 35% of patients reporting no signiﬁcant bar-
riers to donation. The top concerns for our donors included
worry about the patient, ability to take time off to donate,
travel, and fear of pain or other requirements of the
procedure.
Conclusion: The feedback from the donor satisfaction survey
has been valuable both for our program and for staff morale.
The feedback has been overwhelmingly positive, and our
donor comments are shared with the staff quarterly. A
committee has been formed to review donor feedback and
identify areas for improvement. Going forward we hope to
expand this survey to include pediatric patients, and to
develop new donor material tailored to the feedback we’ve
received.162
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Informed Consent for transplant patients is not only a
requirement by law but an integral part of the patient edu-
cation. Transplant centers often use treatment plans for
standard of care. It is a daunting challenge to maintain and
update treatment plan consent forms.
Over the past 20 years, transplant centers have diversiﬁed
and now use multiple conditioning and graft versus host
disease (GVHD) prophylaxis regimens. In transplant centers
that have been in operation for many years, the use of con-
sents for standard of care treatment plans have been
augmented and changed as needed over time. These changes
are due to the introduction of novel therapies, newly iden-
tiﬁed side effects, changes in regulatory and legal re-
quirements and standardization of terminology.
Standardizing the language of consents presents several
dilemmas.
 Should we try to create a treatment plan consent that
could be used for multiple treatment plans?
◦ Will this be confusing for patients?
◦ Will physicians forget to check the boxes for speciﬁc
drugs that are being used?
 Should we describe side effects by organ system or by
drug or both?
 Should we list side effects in a table?
 Should we incorporate blank spaces for personalized
information to be completed by the MD at the time of
consent?
◦ Will this be more cumbersome for physicians?
